Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• The Role of Vaccination in Preventing Pneumococcal Pneumonia

  Pneumococcal pneumonia remains a significant threat to respiratory health, particularly among older adults, young children, and people living with chronic medical conditions. It is caused by Streptococcus pneumoniae, a bacterium that can invade the lungs and, in severe cases, spread into the bloodstream or central nervous system.

  Vaccination provides a well-established method of reducing the risk of invasive pneumococcal disease and pneumonia caused by vaccine-covered serotypes. Its value extends beyond individual protection: high vaccination coverage can reduce transmission and help protect people who are medically vulnerable or unable to receive certain vaccines.

  For respiratory specialists, primary care teams, and public health professionals, pneumococcal immunization is an important part of preventive medicine. Education, accurate risk assessment, and consistent use of national recommendations can improve protection across the community.

  Why Pneumococcal Pneumonia Remains a Concern

  Pneumococci can colonize the upper airway without causing symptoms, yet they may produce serious infection when the immune system is weakened or the respiratory tract is already compromised. Pneumococcal pneumonia can lead to hospitalization, respiratory failure, sepsis, and prolonged recovery.

  The risk is higher in people aged 65 and above, children under five, and individuals with chronic lung disease, cardiovascular disease, diabetes, kidney disease, or immune suppression. Smoking, alcohol dependence, cochlear implants, and the absence of a functioning spleen may also increase the likelihood of severe disease.

  How Immunization Reduces Respiratory Risk

  Pneumococcal vaccines train the immune system to recognize specific capsules, or serotypes, found on the surface of the bacterium. If exposure occurs later, immune defenses can respond more rapidly and reduce the chance that colonization will develop into invasive infection or severe pneumonia.

  Current vaccines include pneumococcal conjugate vaccines, such as PCV15 and PCV20, and pneumococcal polysaccharide vaccine, commonly known as PPSV23. Conjugate vaccines generate a strong immune response and are especially important in childhood immunization programs, while adult schedules may use one vaccine or a sequence based on age, health status, and previous vaccination.

  Vaccine effectiveness varies according to age, immune function, circulating serotypes, and the type of pneumococcal disease. Vaccination cannot prevent every case of pneumonia, but it can substantially lower the risk of vaccine-type infection and severe outcomes.

  Selecting an Appropriate Vaccine Strategy

  Pneumococcal vaccination should follow the schedule recommended by the relevant national health authority. Recommendations differ between countries and may change as new products and surveillance data become available. Clinicians should review previous doses, underlying conditions, contraindications, and the appropriate interval between vaccines.

  The following overview describes common considerations rather than replacing local guidance:

  Population or circumstance	Common vaccination consideration	Clinical priority
  Infants and young children	Routine pneumococcal conjugate vaccination according to the childhood schedule	Complete the primary series and any recommended booster
  Adults aged 65 or older	PCV20 alone, or another approved sequence depending on national policy and history	Check records and offer vaccination during preventive visits
  Chronic heart or lung disease	Adult pneumococcal vaccination based on risk category	Integrate immunization into chronic disease reviews
  Immunocompromised individuals	An enhanced or sequential schedule may be advised	Coordinate timing with specialist care and immunosuppressive therapy
  Previous pneumococcal vaccination	Further doses depend on product, timing, age, and medical risk	Avoid unnecessary duplication while closing protection gaps

  People Who Benefit Most From Protection

  Older adults often have reduced immune responses and a higher probability of hospitalization after pneumococcal infection. Chronic obstructive pulmonary disease, asthma, bronchiectasis, and interstitial lung disease can further reduce respiratory reserve, making prevention especially valuable.

  Children benefit from routine conjugate vaccination because pneumococcal bacteria can cause pneumonia, meningitis, bacteremia, and otitis media during early life. Immunizing children can also reduce carriage and transmission within households, offering indirect protection to older relatives and people with chronic illness.

  People with weakened immunity require careful planning. Cancer treatment, organ transplantation, HIV infection, anatomical or functional asplenia, and certain medications may influence the timing and selection of vaccines. A personalized plan should account for both disease-related risk and the patient’s treatment schedule.

  Integrating Vaccination Into Respiratory Care

  Pneumococcal immunization works best when it is included in routine clinical workflows rather than offered only during seasonal campaigns. Respiratory clinics can review vaccination status during pulmonary function appointments, exacerbation follow-ups, hospital discharge planning, and consultations for chronic lung disease.

  Clear communication helps address concerns about side effects and effectiveness. Most reactions are mild, such as soreness at the injection site, fatigue, or a low-grade fever. Serious adverse events are uncommon, while the consequences of invasive pneumococcal disease can be substantial.

  Vaccination should complement other preventive measures, including smoking cessation, influenza immunization, appropriate COVID-19 vaccination, hand hygiene, nutrition, and management of chronic conditions. Together, these measures support stronger respiratory resilience.

  Practical Steps for Improving Vaccine Uptake

  Healthcare organizations and clinical teams can strengthen pneumococcal disease prevention by:

  • Checking vaccination records whenever patients attend primary care, respiratory, or hospital services.
  • Using electronic reminders and standing orders to identify eligible patients.
  • Explaining the benefits and expected side effects in clear, accessible language.
  • Coordinating vaccine timing with chemotherapy, transplant care, and other immunosuppressive treatments.
  • Recording administered doses accurately so future clinicians can make safe decisions.

  Professional education also matters. Congresses and respiratory medicine meetings provide opportunities to share surveillance findings, review changing vaccine schedules, and discuss strategies for reaching underserved populations. Collaboration between specialists, primary care providers, pharmacists, and public health teams can reduce missed opportunities.

  Turning Prevention Into Respiratory Practice

  Preventing pneumococcal pneumonia requires more than having effective vaccines available. Patients need timely recommendations, reliable access, accurate documentation, and guidance tailored to their age and medical history. Healthcare professionals can make these steps part of every relevant respiratory consultation.

  Review local pneumococcal immunization guidance, identify patients at elevated risk, and build vaccination assessment into everyday care. Consistent action can reduce severe respiratory infections, protect healthcare capacity, and help more patients maintain healthy, independent lives.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)